Sartorius and Sanofi Collaborate on Advanced Bioprocessing Platform

Sartorius, a renowned life science group, has partnered with biopharmaceutical giant Sanofi to develop and commercialize an innovative end-to-end platform for downstream process intensification. This cooperation aims to revolutionize biomanufacturing processes by integrating continuous bioprocessing (ICB) methods to enhance efficiency, reduce resource use, and increase productivity.

The collaboration will see Sartorius leverage its manufacturing and engineering expertise alongside Sanofi’s patents and knowledge in ICB platforms. Sartorius will handle the commercialization, offering these advanced bioprocess solutions on a global scale. This partnership underscores Sartorius’s commitment to innovation in biopharmaceutical manufacturing, which is critical as the industry pushes towards more sustainable and cost-effective production practices.

ICB platforms are expected to play a crucial role in the biopharmaceutical sector by enabling continuous production flow and reducing environmental impacts. This modular approach not only minimizes the consumption of energy and raw materials but also brings life-saving medications to patients more quickly than traditional batch processing methods.